Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 4
  1. Administration of non-enteric-coated pancreatic enzyme replacement tablets with meals and snacks with concurrent dosing with a histamine2 blocker. Non-enteric-coated pancreatic enzyme replacement with concurrent histamine2-blocker dosing will deliver active enzymes to the proximal small bowel and help reduce the malabsorption and steatorrhea that this patient is experiencing. Enteric-coated enzyme preparations can also be effective, but they are more expensive and, when administered with calcium-containing antacids, can worsen steatorrhea by complexing with fatty acids, thus making absorption more difficult. Institution of a low-fat diet can worsen malnutrition; a normal allowance of fat intake (up to 40 g/day) can result in greater patient compliance. Octreotide is often an effective agent for treating the pain of chronic pancreatitis, but it does not enhance food absorption. Placement of pancreatic duct stents also may aid in the treatment of pain in patients with dilated pancreatic ducts, but the stents do not improve digestive capacity.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj